Veterinary Medicine - August 2007 - (Page 534b)

Quick facts I Trial subjects: Eight healthy dogs I Age: Approximately 6 years old I Body weight: 33 to 62 lbs I Sex: Four males, four females and regular monitoring are recommended for pets on any medication, including PREVICOX. Use with other NSAIDs, corticosteroids or nephrotoxic medication should be avoided. Refer to the prescribing information for complete details or visit www.previcox.com. The subjects and methods Eight healthy, mixed-breed dogs participated in the positivecontrol, blinded, four-period crossover design study. The 21-day study included four treatment periods separated by a seven-day washout period. On Days 0, 7, 14, and 21, each dog was orally administered one of four NSAIDs (firocoxib, carprofen, deracoxib, and meloxicam) at the approved label dosages for osteoarthritis. Ten hours later, each dog was injected with urate crystals in the stifle joint to induce synovitis and lameness. Injections were alternated between the dogs’ left and right stifle. The efficacy of each NSAID to prevent pain and inflammation Figure 1. Lameness scores were lowest with firocoxib 5 was assessed in two ways. A force plate gait analysis of ground reaction force was performed using a floor-mounted force platform. The device measured in peak vertical force the amount of weight the dog put on the injected leg. Dogs were trotted across the device within 24 hours before each injection to establish a baseline and then 14 and 18 hours (four and eight hours after urate crystal injection, respectively) after each NSAID was administered. During each force plate gait observation, the injected leg was given a lameness score from 0 to 4, which was assessed as follows: • 0 = no lameness • 1 = mild lameness (including toe touch to floor [i.e., weight bearing] on all strides) • 2 = moderate lameness (including toe touch to floor on all strides but was less weight bearing) • 3 = severe lameness (including toe touch to floor on 50% or more of the strides) • 4 = non-weight bearing lameness (including toe touch to floor on less than 50% of the strides) Results Lameness score 4 3 I Firocoxib (5 mg/kg) I Carprofen (4.4 mg/kg) I Deracoxib (1 to 2 mg/kg) I Meloxicam (0.2 mg/kg) 2 1 0 Hour 14 (peak lameness) Hour 18 Time after treatment Figure 1. Lamness score results from 0 (no lameness) to 4 (non-weight bearing lameness) at hours 14 and 18 (four and eight hours after urate crystal injection). (No claim of superiority can be made from these data.) At hour 14, when the urate crystal lameness effect was at its peak, dogs administered firocoxib averaged a 0.75 lameness score (Figure 1). Dogs given the other NSAIDs averaged lameness scores of 1.63 to 2.00. The same trend continued in hour 18, with firocoxib averaging 0.25 and the other NSAIDs averaging 0.75 to 1.25. At hour 14, dogs administerd firocoxib demonstrated 85% of http://www.previcox.com

Table of Contents Feed for the Digital Edition of Veterinary Medicine - August 2007

Contents A Veterinary Medicine Interview Veterinary Voices Idea Exchange Diagnosis and Treatment of Solar Dermatitis in Dogs Diagnostic Imaging for Linear Foreign Bodies in Cats Overcoming the Diagnostic and Therapeutic Challenges of Canine Immune-Mediated Thrombocytopenia Ophthalmic drugs: What’s new? CE Form Product Preview Advertiser Index Marketplace/Classifieds Mind Over Miller

Veterinary Medicine - August 2007

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.